Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.

Jan-Michael WernerJohannes WellerGarry CecconChristina SchaubCaroline TscherpelPhilipp LohmannElena K BauerNiklas SchäferGabriele StoffelsChristian BauesEren CelikSimone MarnitzChristoph KabbaschGerrit H GielenGereon R Fink Karl-Josef LangenUlrich HerrlingerNorbert Galldiks

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The data suggest that FET-PET parameters are of significant clinical value to diagnose pseudoprogression related to lomustine-temozolomide chemoradiation.

Keyphrases

newly diagnosed
rectal cancer
end stage renal disease
positron emission tomography
computed tomography
pet ct
locally advanced
ejection fraction
peritoneal dialysis
machine learning
prognostic factors
patient reported
data analysis
artificial intelligence